Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~All subjects must satisfy ALL of the following criteria at study entry:~* Subjects whom the investigator believes that they and/or their parent(s)/Legally Acceptable Representative(s) can and will comply with the requirements of the protocol.~* A male or female between, and including, 10 and 25 years of age at the time of the vaccination.~* Written informed consent obtained from the subject/from the parent or Legally Acceptable Representative(s) of the subject. Assent will be obtained from subjects who are still legally minors in line with local rules and regulations.~* Healthy subjects as established by medical history and clinical examination before entering into the study.~* Previously completed routine childhood vaccinations to the best of subject's/Legally Acceptable Representative(s)'s knowledge.~* Female subjects of non-childbearing potential may be enrolled in the study.~* Female subjects of childbearing potential may be enrolled in the study, if the subject:~  * has practiced adequate contraception for 30 days prior to vaccination, and~ * has a negative pregnancy test on the day of vaccination, and~ * has agreed to continue adequate contraception for 2 months after vaccination.~Exclusion Criteria:~The following criteria should be checked at the time of study entry. If ANY exclusion criterion applies, the subject must not be included in the study:~* Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the dose of study vaccine, or planned use during the study period.~* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to vaccination. (For corticosteroids, this will mean prednisone \<10 mg/day, or equivalent, is allowed. Inhaled and topical steroids are allowed.)~* Planned administration/administration of a vaccine not foreseen by the study protocol within one month of the dose of vaccine, with the exception of any licensed inactivated influenza vaccine.~* Previous vaccination with meningococcal polysaccharide or conjugate vaccine.~* Previous vaccination with vaccine components within the last month.~* History of meningococcal disease.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus infection, based on medical history and physical examination.~* A family history of congenital or hereditary immunodeficiency, until the immune competence of the potential vaccine recipient is demonstrated.~* History of allergic reactions or disease likely to be exacerbated by any component of either vaccine, or by dry natural rubber latex.~* History of any neurologic disorders, including Guillain-Barré Syndrome.~* Major congenital defects or serious chronic illness.~* Acute disease at the time of enrollment.~* Administration of immunoglobulins and/or any blood products within the three months preceding the dose of study vaccine or planned administration during the study period.~* Pregnant or lactating female.~* History of chronic alcohol consumption and/or drug abuse.~* Female planning to become pregnant or planning to discontinue contraceptive precautions.~* Bleeding disorders, such as thrombocytopenia, or subjects on anti-coagulant therapy.~* Child in care.~* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 25 Years
- Healthy Volunteers: t

Study Arms:
- Group A (Type: EXPERIMENTAL): Subjects were vaccinated with vaccine GSK134612 Lot A
- Group B (Type: EXPERIMENTAL): Subjects were vaccinated with vaccine GSK134612 Lot B
- Group C (Type: ACTIVE_COMPARATOR): Subjects were vaccinated with Menactra®

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete